2016
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Goss P, Ingle J, Pritchard K, Robert N, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Journal Of Clinical Oncology 2016, 34: lba1-lba1. DOI: 10.1200/jco.2016.34.18_suppl.lba1.Peer-Reviewed Original ResearchEarly-stage breast cancerYears of tamoxifenAromatase inhibitor therapyDisease-free survivalBreast cancerAI treatmentPostmenopausal womenInhibitor therapyHormone receptor-positive early breast cancerReceptor-positive early breast cancerTwo-sided log-rank testDisease-free survival eventsPositive early breast cancerPrior adjuvant chemotherapyPlacebo-controlled trialYear overall survivalContralateral breast cancerEarly breast cancerAnnual incidence rateStage breast cancerLog-rank testStandard of careBreast cancer recurrenceAdjuvant chemotherapyAdjuvant letrozoleA randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Goss P, Ingle J, Pritchard K, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff A, Winer E, Hudis C, Stopeck A, Beck J, Kaur J, Whelan K, Tu D, Parulekar W. A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. Journal Of Clinical Oncology 2016, 34: lba1-lba1. DOI: 10.1200/jco.2016.34.15_suppl.lba1.Peer-Reviewed Original Research
2015
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. Journal Of Clinical Oncology 2015, 33: 2772-2779. PMID: 26215945, PMCID: PMC4550691, DOI: 10.1200/jco.2015.60.8133.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansKi-67 AntigenLetrozoleMiddle AgedNitrilesReceptor, ErbB-2TamoxifenTreatment OutcomeTriazolesConceptsInvasive ductal carcinomaInvasive lobular carcinomaDisease-free survivalLobular carcinomaDFS eventsDuctal carcinomaLA subtypeBreast International Group (BIG) 1Early-stage invasive ductal carcinomaClassic invasive lobular carcinomaHER2-negative invasive ductal carcinomaKi-67 labeling indexLow proliferative activityMagnitude of benefitAdjuvant letrozoleMedian followBIG 1ILC subsetsMultivariable modelCox modelGroup 1LetrozoleCarcinomaLabeling indexPatients